Optimising Molecular Radionuclide Therapy

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

October 20, 2022

Study Completion Date

November 5, 2022

Conditions
Neuroendocrine TumorsHyperthyroidismThyroid CancerThyroid Carcinoma
Interventions
DIAGNOSTIC_TEST

Nuclear Medicine whole-body

Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).

DIAGNOSTIC_TEST

SPECT/CT imaging.

SPECT/CT scan at 24-48 hr post MRT

DIAGNOSTIC_TEST

PET/CT imaging.

3-6 months Pre and post-therapy PET/CT imaging

DEVICE

Patient-led radiation monitor (SELFIE)

"Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire."

DIAGNOSTIC_TEST

LAB TEST

Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.

Trial Locations (1)

SE1 9RT

Guy's and St Thomas Hospitals Foundation Trust, London

All Listed Sponsors
collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

lead

King's College London

OTHER